
|Articles|September 27, 2014
- Head and Neck Cancers (Issue 2)
- Volume 2
- Issue 1
Sequencing Sorafenib and Lenvatinib in Thyroid Cancer
Author(s)Marcia S. Brose, MD, PhD, FASCO
Marcia S. Brose, MD, PhD, discusses using both sorafenib and lenvatinib as treatment options for thyroid cancer.
Advertisement
Articles in this issue
over 11 years ago
Treatment Update: Unresectable Medullary Thyroid Cancerover 11 years ago
The Side Effects of Lenvatinibover 11 years ago
Immune Checkpoint Inhibitors for Head and Neck Cancersover 11 years ago
Battling the Immunosuppressive Nature of Head and Neck CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Relacorilant Demonstrates Significant OS in Platinum-Resistant Ovarian Cancer
2
Oncologists Weigh BTK/BCL2 Inhibitor Combinations in CLL
3
FDA OKs Guardant360 CDx for Encorafenib Combo in BRAF V600E+ Metastatic CRC
4
Later-Line and Combination Therapies in cGVHD and Future Directions
5




















